Pharmacogenomics in early-phase oncology clinical trials: Is there a sweet spot in phase II?

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2809-2816

  O'Donnell, Peter H ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; IRINOTECAN; OXALIPLATIN; TUMOR MARKER;

COLORECTAL CANCER; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; GENE FUNCTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC TOXICOLOGY; GENETIC VARIABILITY; GERM LINE; HUMAN; ONCOLOGY; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR GENE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861123738     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2445     Document Type: Review

References (37)

1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011;364:1144-53.
2. Watson RG, McLeod HL. Pharmacogenomic contribution to drug response. Cancer J 2011;17:80-8.
3. Lander ES, Linton LM, Birren B, NusbaumC, Zody MC, Baldwin J, et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001;409: 860-921. (Pubitemid 32165345) (Pubitemid 32165345)
4. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291:1304-51. (Pubitemid 32173090)
5. United States Food and Drug Administration. Rockville (MD): United States Food and Drug Administration. Cetuximab (erbitux) and panitumumab (vectibix). 2010 updated January 11, 2010 [cited March 29, 2011]; Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/ucm172905.htm.
6. Armour AA, Watkins CL. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur Respir Rev 2010;19: 186-96.
7. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
8. Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol 2001;12[Suppl 1]:S49-55. (Pubitemid 32750585)
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155) (Pubitemid 32222155)
10. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-63. (Pubitemid 39383023) (Pubitemid 39383023)
11. Zarate R, Rodríguez J, Bandres E, Patĩno-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010;102:987-94.
12. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol 2007;25:4513-5. (Pubitemid 350035302)
13. van den Oord EJ. Controlling false discoveries in genetic studies. AmJ Med Genet B Neuropsychiatr Genet 2008;147B:637-44.
14. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al.NCI-NHGRI Working Group on Replication in Association Studies. Replicating genotype-phenotype associations. Nature 2007;447:655-60.
15. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56. (Pubitemid 30407863) (Pubitemid 30407863)
16. Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 2010;5:932-4.
17. Wieand HS. Randomized phase II trials: what does randomization gain? J Clin Oncol 2005;23:1794-5. (Pubitemid 46211355) (Pubitemid 46211355)
18. Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006;62:35-46. (Pubitemid 44195241)
19. Stadler WM. The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther 2007;6:1180-5. (Pubitemid 46711981)
20. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapynaive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24:3340-6. (Pubitemid 46638887) (Pubitemid 46638887)
21. Ribas A, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J, et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011;29:8509.
22. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, et al. Australian Ovarian Cancer Study Group. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its associationwith outcome in ovarian cancer patients. Clin Cancer Res 2011;17:5490-500.
23. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009;301: 393-403.
24. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Gloghini A, et al. The host genetic background ofDNArepair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood 2011;117: 2405-13.
25. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 2006;7: 1211-21. (Pubitemid 46024184)
26. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004;26:186-91. (Pubitemid 38501216)
27. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009;15:4806-14.
28. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-6.
29. Frueh FW. Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 2009;10:1077-81.
30. Stingl Kirchheiner JC, Brockmöller J. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. Clin Pharmacol Ther 2011;89:198-209.
31. Pusztai L. Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pharmacogenomics 2007;8:1443-8. (Pubitemid 350162856) (Pubitemid 350162856)
32. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 2007;13:6080-6. (Pubitemid 350075065) (Pubitemid 350075065)
33. Temple RJ. Enrichment designs: efficiency in development of cancer treatments. J Clin Oncol 2005;23:4838-9. (Pubitemid 46223984)
34. Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, et al. The maximum tolerated dose and biologic effects of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol 2010;66:973-80.
35. Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, et al. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemother Pharmacol 2008;62:1075-83.
36. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, et al. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 2008;26:369-79.
37. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009; 27:2163-9.